News

Osiris Therapeutics has announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). Prochymal showed significant improvements in

BHR Pharma (BHR) has reported that it will initiate phase 3, multi-center pivotal trial to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a

Seattle Genetics has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma. The milestone was triggered by Bayer’s submission of an Investigational New Drug

Aeolus Pharmaceuticals (Aeolus) has initiated a study to confirm the efficacy of AEOL 10150 as a countermeasure to nuclear and radiological exposure in non-human primates. AEOL 10150 has

Navitus Health Solutions (Navitus) has signed contracts to provide pharmacy benefits to three government trusts in Arizona. The contracts are with the Arizona Local Government Employee Benefit Trust

ISTA Pharmaceuticals (ISTA) has reported preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). Reportedly, the

Protalix BioTherapeutics (Protalix) has received notice from the FDA that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD. prGCD is company’s proprietary

Swiss pharmaceutical and retail company Galenica has acquired the entirety of OM PHARMA, a biotechnology and pharmaceutical Swiss company. Acquisition is expected to increase Galenica’s internationalisation by contributing

Vical has received $2.5m installment payment from AnGes for the company’s ongoing Allovectin-7 phase 3 metastatic melanoma trial. Reportedly, through a series of cash payments and equity investments